Abstract
To better define high-risk populations for colorectal cancer screening, we used anti-adenoma antibody Adnab-9, comparing colonic effluent and tissue field effects from 45 high-risk and 11 control patients. We included Adnab-9 binding at the tissue level to elucidate the impact of a field effect of carcinogenesis contributing to the outcome of the effluent binding test. In high-risk patients, 64% of the left-sided effluent samples were positive (P < 0.002); 67% showed a field effect (P < 0.006); 82% of combined tests were positive (P < 0.001), as compared to 9%, 18%, and 27% respectively, of controls. Adnab-9 binding correlates with increased colorectal cancer risk associated with a field effect of carcinogenesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Darmon E, Tobi M, Rozen P: Newer tests, on the colonic effluent, for identifying persons with colorectal neoplasia. In Frontiers of Gastrointestinal Research, Advances in Large Bowel Cancer: Policy, Prevention, Research and Treatment. P Rozen, CB Reich, SJ Winawer (eds). Basel Karger, 1991, pp 236–247
Rozen P, Tobi M, Darmon E, Kaufman L: Colonic cytology: A simplified method of collection and initial results. Acta Cytol 34:627–631, 1990
Tobi M, Feng-Chi L, Ronai A: Detection of K-ras mutation in colonic effluent samples from patients without evidence for colorectal carcinoma. J Natl Cancer Inst 86:1007–1010, 1994
Tobi M, O'Kieffe D, Trujillo N, Nochomovitz LE, Steinberg WM: Detection of carcinoembryonic antigen in colonic effluent by specific anti-CEA monoclonal antibodies. Cancer Lett 67:47–54, 1992
Tobi M, Steinberg W, Henry J, Nochomovitz LE: Cancer associated antigen CA19–9 in colonic effluent of patients with neoplasia of the colon and inflammatory bowel disease. Cancer Lett 60:9–13, 1991
Kristinsson J, Roseth A, Fagerhol MKR, Aadland E, Schjonsby H, Bormer OP, Raknerud N, Nygaard K: Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41:316–321, 1998
Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of the ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102–105, 1992
Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP: Colorectal cancer screening by deletion of altered human DNA in the stool: feasibility of a multitarget assay panel. Gastroenterology 119:1219–1227, 2000
Tobi M: Polyps as biomarkers. Front Biosci 4:d329–388, 1999; www.bioscience.org
Tobi M, Darmon E, Phillips T, Heller T, Rozen P, Nochomovitz LE, Steinberg WM: Increased expression of a putative adenoma associated antigen in precolonoscopic effluent of patients with colorectal cancer. Cancer Lett 51:21–25, 1990
Tobi M, Maliakkal BJ, Zitron I, Alousi M, Goo BG, Nochomovitz LE, Luk GD: Colonic effluent adenoma-associated antigen correlated with colorectal cancer is a membrane-bound glycoprotein. Cancer Lett 67:61–69, 1992
Tobi M, Elitsur Y, Moyer MP, Halline A, Deutsch M, Nochomovitz L, Luk GD: Mucosal origin and shedding of an early colonic tumor marker defined by Adnab-9 monoclonal antibody. Scand/J Gastroenterol 28:1025–1034, 1993
Tobi M, Darmon E, Rozen P, Epstein N, Konikoff F, Stadler Y, Harpaz N, Fink AK, Bentwich Z, Maliakkal B, Luk GD: Oral colon lavage solutions may interfere with ELISA detection of tumor associated antigens in colonic effluent. Dig Dis Sci 36:1448–1452, 1991
Tobi M, Darmon E, Rozen P, Avigdor S, Rattan J, Santo M, Barnea E: Biotransformation in colorectal neoplasia. Scand J Gastroenterol 28:958–962, 1993
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with Folin phenol reagent. J Biol Chem 193:265–275, 1951
Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 112:594–642, 1997
Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. Ca Cancer J Clin 50:7–33, 2000
Powell J: Katie's crusade. Good Housekeeping October: 124–192, 1998
Smith RA, Mettlin CJ, Davis KJ, Eyre H: American Cancer Society guidelines for the early detection of cancer. Ca Cancer J Clin 50:34–49, 2000
Rozen P: Screening for colorectal neoplasia in the Tel Aviv area: Cumulative data 1979-89 and initial conclusions. Isr J Med Sci 28(1 suppl):8–20, 1992
Yuan M, Xhang X, Leu Y, Tobi M: Sensitivity of fecal Adnab-9 testing for colorectal neoplasia. Gastroenterology, 110:A619, 1996 (abstract)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tobi, M., Prabhu, S., Gage, R.E. et al. Colorectal Cancer Risk: The Impact of Evidence of a Field Effect of Carcinogenesis on Blinded Diagnosis Using an Anti-Adenoma Antibody Test Performed on Colonoscopic Effluent. Dig Dis Sci 47, 317–321 (2002). https://doi.org/10.1023/A:1013713920805
Issue Date:
DOI: https://doi.org/10.1023/A:1013713920805